Belite Bio (BLTE) Total Non-Current Liabilities (2024 - 2025)
Belite Bio (BLTE) posted quarterly Total Non-Current Liabilities of $188000.0 for Q4 2025, down 27.97% year-over-year from $261000.0 in Q4 2024, and down 97.74% quarter-over-quarter from $8.3 million in Q3 2025.
Powered by 
Analysis
Belite Bio (BLTE) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Belite Bio's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $188000.0 for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 27.97% year-over-year to $188000.0; the TTM figure through Dec 2025 stood at $188000.0 (down 27.97% YoY), while the FY2025 annual figure was $188000.0, down 27.97% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $188000.0, down from $8.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $8.3 million in Q3 2025, with the low at $188000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Belite Bio | 6.44 Bn | 6.44 Bn | - | - |